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Abstract
Background: Women with polycystic ovary syndrome (PCOS) are often treated with insulin-
sensitizing agents, e.g. thiazolidinediones (TZD), which have been shown to reduce androgen levels
and improved ovulatory function. Acting via peroxisome proliferator-activated receptor (PPAR)
gamma, TZD alter the expression of a large variety of genes. Lethal yellow (LY; C57BL/6J Ay/a)
mice, possessing a mutation (Ay) in the agouti gene locus, exhibit progressive obesity, reproductive
dysfunction, and altered metabolic regulation similar to women with PCOS. The current study was
designed to test the hypothesis that prolonged treatment of aging LY mice with the TZD,
pioglitazone, alters the ovarian expression of genes that may impact reproduction.
Methods: Female LY mice received daily oral doses of either 0.01 mg pioglitazone (n = 4) or an
equal volume of vehicle (DMSO; n = 4) for 8 weeks. At the end of treatment, ovaries were removed
and DNA microarrays were used to analyze differential gene expression.
Results: Twenty-seven genes showed at least a two-fold difference in ovarian expression with
pioglitazone treatment. These included leptin, angiopoietin, angiopoietin-like 4, Foxa3, PGE1
receptor, resistin-like molecule-alpha (RELM), and actin-related protein 6 homolog (ARP6). For
most altered genes, pioglitazone changed levels of expression to those seen in untreated C57BL/
6J(a/a) non-mutant lean mice.
Conclusion: TZD administration may influence ovarian function via numerous diverse
mechanisms that may or may not be directly related to insulin/IGF signaling.
Background
Polycystic ovary syndrome (PCOS) is a reproductive dis-
order characterized by chronic anovulatory ovarian folli-
cles and hyperandrogenism, often associated with obesity.
It is the major cause of anovulatory infertility, affecting
approximately 5–10% of women of reproductive age.
PCOS is one of several health disorders associated with
Metabolic Syndrome (Syndrome X), or subclinical insulin
resistance. A decrease in insulin sensitivity leads to a com-
pensatory increase in insulin secretion to maintain nor-
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a major contributing factor to the hyperandrogenism and
ovulatory dysfunction in PCOS [1,2].
It has become common practice to treat women with
PCOS with insulin-sensitizing drugs. The two classes of
insulin-sensitizing agents currently used most often in
clinical practice are biguanides (e.g. metformin) and thia-
zolidinediones (TZD), which include rosiglitazone and
pioglitazone. These classes of drugs act via different mech-
anisms which are not thoroughly understood. In general,
metformin reduces hepatic glucose synthesis leading to a
direct reduction in insulin secretion [3]. TZD are ligands
for the peroxisome proliferator-activated receptor γ
(PPARγ), which enhances transcription of a variety of
genes that collectively promote glucose disposal.
Metformin has been much more widely used and studied
in women with PCOS than have TZD. Women treated
with metformin have significantly improved spontaneous
ovulation and ovulatory response to gonadotropins,
diminished androgen levels, lowered blood pressure, and
enhanced fertility [4-7]. Limited studies with TZD have
shown similar results [8,9].
Although overall improvement in symptoms appears to
be similar with metformin or TZD, these drugs clearly act
via distinct mechanisms. For example, TZD (troglita-
zone), but not metformin, reduced androgen levels by
directly suppressing 3β-hydroxysteroid dehydrogenase
and cytochrome P450 17α-hydroxylase, two key enzymes
in the androgenic pathway [10]. Moreover, insulin and
insulin-like growth factor cellular signaling were differen-
tially altered in ovarian cells from women with PCOS, but
after TZD treatment cell signaling was similar to cells from
non-PCOS women [11]. In that study, insulin receptor
substrate (IRS)-1 and -2 expression by ovarian granulosa
cells from women with PCOS was altered relative to cells
from women without PCOS; IRS-1 expression was higher
and IRS-2 expression was lower in PCOS cells. However,
after troglitazone treatment in vitro, IRS-1 expression was
reduced and IRS-2 expression was enhanced bringing the
levels of expression similar to those found in non-PCOS
cells [11].
Mice heterozygous for the Lethal Yellow (LY) mutation at
the agouti locus exhibit distinct characteristics including
yellow coat color, adult onset obesity, and accelerated
reproductive senescence [12]. Moreover, as these mice
age, they progressively develop insulin resistance and
hyperinsulinemia [13], hyperleptinemia [14], and central
leptin resistance [15]. Diminishing ovarian function in
aging LY mice is directly related to increasing obesity and
the progression of altered metabolic regulation [16]. LY
mice provide a useful animal model for investigating the
effects of insulin-sensitizing drugs on ovarian gene expres-
sion in a hyperinsulinemic/insulin resistant state. The cur-
rent study tested the hypothesis that chronic treatment of
aging LY mice with the insulin-sensitizing drug, pioglita-
zone, alters the ovarian expression of genes that may be




The study was approved by the Augustana College Animal
Care and Use Committee. Black (BL; C57BL/6J a/a) and
Lethal Yellow (LY; C57BL/6 Ay/a) mice from the Augus-
tana College Biology Department breeding colony were
used for the study. Founder mice were originally obtained
from Jackson Laboratory (Bar Harbor, ME, USA). Mice
were fed maintenance diet (Harlan Teklad, Madison, WI,
USA) and fresh water ad libitum, and housed in groups of
four mice per cage on a 14:10 light/dark cycle with lights
on at 0600 as described previously [16]. Beginning at 120-
days of age, female LY mice received daily oral doses of
either 0.01 mg pioglitazone (n = 4 mice) or an equal vol-
ume of vehicle (DMSO; n = 4 mice) for 60 consecutive
days. This dosage of pioglitazone was chosen to approxi-
mate the dosage used clinically in humans after adjust-
ment for body mass, i.e. 30 mg daily for a 50–70 kg adult.
At the end of the treatment regimen, the now 180-day old
treated LY mice and untreated 180-day old C57BL/6J non-
mutant control mice (n = 2) were weighed and then euth-
anized by cervical dislocation after overnight fasting. For
all mice, blood was collected by heart puncture, glucose
concentrations were measured immediately on whole
blood, and serum was processed and stored at -20C for
later analyses. Both ovaries were removed and carefully
trimmed of adhering fat and connective tissue. One ovary
from each animal was quickly placed in RNALater
(Ambion, Austin, TX) for subsequent RNA extraction. The
contralateral ovary was placed in cell lysis buffer (Sigma),
homogenized, centrifuged, and protein extracts were
stored at -80C for later Western blot analysis.
Hormone and glucose assays
Glucose was measured in fresh whole blood using a Free-
style (TheraSense, Alameda, CA) glucometer, linear range
= 20–500 mg/dL. Leptin concentrations were measured in
serum in a single run using a homologous Mouse Leptin
RIA kit (Linco Research, St. Louis, MO, USA) as described
previously [16]. The interassay CV was 3.3%. Insulin was
measured using the Mercodia Ultrasensitive Mouse Insu-
lin ELISA (ALPCO Diagnostics, Windham, NH). The sam-
ple volume was 5 μl. Intraassay CV was 6.2% and
interassay CV was 5.1%.Page 2 of 8
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RNA was extracted as described [17]. Each ovary was
homogenized in 1 ml TRI reagent (Molecular Research
Center, Cincinnati, OH). Sodium acetate and bromochlo-
ropropane were mixed with the homogenate, the sample
was incubated on ice for 15 min, and then centrifuged to
separate the phases. The aqueous phase containing RNA
was removed and purified on an Rneasy column (Qiagen,
Valencia, CA). The sample was treated with an on-column
RNase-free DNase to remove any potentially contaminat-
ing genomic DNA. Total RNA was eluted from the col-
umn. The RNA concentration and purity were calculated
using the RNA 6000 Nano LabChip in an Agilent Bioana-
lyzer. The RNA was stored at -70°C prior to processing for
DNA microarray analysis.
Microarrays
CodeLink Whole Mouse Genome Bioarrays (GE/Amer-
sham, Piscataway, NJ, now Applied Micrarrays, Tempe,
AZ) were used for the analysis of differential gene expres-
sion in this study. These microarrays contain 33,000 sin-
gle-stranded 30-mer oligonucleotide probes for mouse
genes and transcribed sequences. Biotinylated comple-
mentary RNA (cRNA) probes were synthesized from the
extracted RNA samples per company directions as previ-
ously described [17] using CodeLink Expression Assay
Reagent Kit (GE-Amersham Biosciences). Individual sam-
ples were run on separate microarrays (n = 4/LY treatment
group; n = 2 for BL controls); no samples were pooled.
The biotinylated cRNA was fragmented and hybridized
with the DNA microarray slides for 18 hours at 37°C. The
hybridized slides were washed and incubated with
streptavidin-Alexa Fluor 647 (Molecular Probes) to label
the cRNA, and washed again. An Axon GenePix Scanner
was used to scan the microarrays. GenePix Pro software
(MDS, Inc., Toronto, ON) was used to acquire and align
the microarray image. CodeLink software (Applied Micro-
arrays, Tempe, AZ) applied the background correction.
GeneSpring 7.0 software (Agilent, Santa Clara, CA) was
used to normalize the expression of each gene to the
median gene expression and to normalize each slide to
the the 50th percentile of gene expression. Statistical anal-
ysis of the data was performed using GeneSpring 7.0 (Agi-
lent). The p value was set at 0.05 for the t test. Multiple
testing correction used the Benjamini and Hochberg False
Discovery Rate. Approximately 5% of the genes would be
expected to pass this restriction by chance with this test.
Real time RT-PCR
Real time RT-PCR was used to confirm differential gene
expression of resistin-like molecule alpha (RELMα).
Attempts to confirm three additional genes, leptin, ARP6,
and angiopoietin-like 4, were inconclusive and could not
be repeated due to depletion of the RNA samples. Pre-
designed primers and fluorescent (FAM) labeled minor
groove binding probe were obtained from Applied Biosys-
tems (Foster City, CA). Real time RT-PCR was carried out
with TaqMan Gold RT-PCR reagents (Applied Biosystems)
as described [17]. Changes in expression of RELMα were
calculated relative to an endogenous control (GAPDH).
An RNA concentration-response validation curve was car-
ried out to determine the concentration of RNA to add to
the RT-PCR reaction. All samples were run in duplicate, n
= 3. The qBase software [18] was used to analyze the data
from the real time RT-PCR reaction. The qBase program
uses a delta Ct (threshold cycle) relative quantitation
model with PCR efficiency correction and multiple refer-
ence gene normalization. The real time RT-PCR data were
analyzed by t-test with GraphPad Prism software (Graph-
Pad Software, San Diego, CA).
Immunocytochemistry
Paraffin sections from 180-day old untreated LY mice that
were available from previous studies were used to confirm
the presence of RELMα in mouse ovary since all ovaries
from the present study were used for other purposes.
VectaStain Rabbit IgG Elite ABC kit (Vector Laboratories,
Inc., Burlingame, CA) was used for immunocytochemis-
try. Sections were de-paraffinized, re-hydrated, and
blocked with 3% hydrogen peroxide in methanol for 15
min. Antigen retrieval pre-treatment was performed by
sequential microwaving in citrate buffer. After washing,
sections were blocked with blocking serum and rinsed.
Sections were incubated with primary antibody (anti-
RELMα; Upstate/Chemicon, Temecula, CA) for 1 h at RT,
washed thrice, and incubated with biotinylated second
antibody for 30 min. at RT. Slides were washed and incu-
bated with VectaStain ABC reagent for 30 min. at RT. DAB
substrate was used for colorimetric antigen detection, and
sections were counterstained with hematoxylin. Each
slide contained three serial tissue sections, one of which
was always incubated without primary antibody to serve
as a control. No staining was observed in any control sec-
tions.
Western blotting
Samples and pre-stained standards (Bio-Rad MagicMark
XP, Invitrogen) were loaded into precast Tris-HCl mini-gel
Table 1: Body weight (BW) and fasting serum concentrations of 
leptin, insulin, and glucose in 180-day old vehicle- and 
pioglitazone-treated LY mice and untreated BL control mice.
Vehicle Pioglitazone Untreated 
C57BL/6J
BW (g) 34.8 ± 5.3 a 34.8 ± 4.4 a 24.1 ± 0.4 b
Leptin (ng/mL) 41.0 ± 11.4 a 43.5 ± 12.4 a 6.7 ± 2.4 b
Insulin (ng/mL) 2.09 ± 0.19 a 1.65 ± 0.35 a 0.85 ± 0.05 b
Glucose (mg/dL) 138 ± 10 a 129 ± 3 a 122 ± 3 a
Means ± SD, n = 4 per group. Letter superscripts denote significant 
differences among groups (ANOVA, Duncans test).Page 3 of 8
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for the stacking gel and 23 mA for the running gel. Pro-
teins were transferred with constant voltage to 7 × 8.5 cm
Biotrace PVDF Transfer Membranes (VWR International,
Inc) for 1 hour at 120 v. Following transfer, the mem-
branes were blocked for 1 hour at room temperature with
5% ECL blocking agent (GE Healthcare) in TBS-Tween.
The membrane was then incubated overnight at 4C in pri-
mary antibody (same as used for immunocytochemistry)
diluted in 1% ECL blocking/TBS-tween. Following three
times five minute washes with TBS-tween, the membrane
was incubated for 1 hour at room temperature with horse
radish peroxidase conjugated secondary antibody (R&D
Systems, Inc). The membrane was washed three times five
minute with TBS-tween before development with Lumi-
Light PLUS Western Blotting Substrate (Roche Diagnostic
Corp). Bands were visualized by enhanced chemilumines-
cence. Relative band intensities were compared by deter-
mining the ratio of the area densities of RELMα to actin
bands for each lane using Image-Pro Plus® software (Medi-
aCybernetics). Ratio means were compared between treat-
ment groups by t-test.
Results
Oral pioglitazone treatment for 60 days in LY mice did not
significantly alter body weight, or fasting serum glucose,
insulin, or leptin levels (Table 1), although fasting insulin
tended (p = 0.09) to be slightly lower in pioglitazone-
treated mice. Body weight, insulin, and leptin levels were
all higher in LY mice than in age-matched, untreated BL
mice.
Of 3.3 × 104 genes on the array, approximately 1500
showed a significant (p < 0.05) difference in expression.
Unidentified genes and expressed sequence tags (EST)
were removed from further analysis. In addition, those
genes whose expression was less than 0.2 relative intensity
units (the limit of sensitivity) in both control and treat-
ment groups were excluded. After these exclusions, 27
genes representing a diversity of function exhibited a 2-
fold or greater significant (p < 0.05) difference in expres-
sion level between groups (Table 2). Genes with reduced
expression in pioglitazone-treated mice included leptin,
angiopoietin, angiopoietin-like 4, Foxa3, and tenascin.
Conversely, RELMα, prostaglandin (PG) D receptor, and
PGE1 receptor all exhibited elevated expression in piogli-Page 4 of 8
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Accession # Δ1 (pioglitazone) Δ2 (C57BL/6J) Gene name
NM_008493.3 0.28 0.17 leptin (Lep)
NM_009640.2 0.35 0.65 angiopoietin (Agpt)
NM_177839.2 0.44 0.61 tenascin N (Tnn)
CF906297.1 0.46 0.37 formyltetrahydrofolate synthetase domain 1
AK083494.1 0.46 0.72 ubiquitin specific protease 29
NM_008260.1 0.47 0.54 forkhead box A3 (Foxa3)
CK329907.1 0.49 0.45 aconitase 2, mitochondrial
AK005115.1 0.50 0.85 zinc-finger RNA-binding domain containing 1
NM_025914.1 0.50 0.65 actin-related protein 6 homolog, ARP6
NM_020581.1 0.50 0.88 angiopoietin-like 4 (Angptl4)
NM_008962.2 2.00 2.54 prostaglandin D receptor (Ptgdr)
NM_178779.2 2.00 2.40 ring finger protein 152
BC025027.1 2.00 1.59 similar to phospholipase C, epsilon
NM_021462.2 2.02 1.92 MAP kinase-interacting ser/thr kinase 2
NM_134249.3 2.04 2.05 T-cell immunoglobulin/mucin domain 2 (Timd2)
NM_011904.1 2.05 1.84 tolloid-like 2 (Tll2)
AK053616.1 2.07 1.77 prostaglandin E receptor 1
NM_009188.1 2.08 2.52 transcriptional regulator, SIN3B (Sin3b)
BY482739.1 2.08 1.54 membrane associated guanylate kinase interacting-1
AI604236.1 2.32 1.50 E74-like factor 1
NM_021447.1 2.50 2.05 ring finger protein 30 (Rnf30)
NM_020509.2 2.62 1.04 resistin-like alpha (RELMα)
NM_008830.1 2.82 2.18 ATP-binding cassette, subfamily B, member 4
NM_148937.1 3.33 1.81 phospholipase Cδ 4
AF223416.1 3.55 1.85 cardiac triadin isoform 2 mRNA
NM_198864.2 3.58 1.91 SLIT and NTRK-like family, member 3 (Slitrk3)
BB393194.2 5.22 0.84 dipeptidylpeptidase 10
Vehicle-treated LY mice (controls) were assigned a level of expression of 1.0 for each gene Relative expression of pioglitazone-treated LY mice (Δ1) 
and untreated BL non-mutant mice (Δ2) compared with control mice is expressed as the fold-difference of the mean level of expression of four 
(vehicle- and pioglitazone-treated) or two (untreated C57BL/6J) animals per group.
Reproductive Biology and Endocrinology 2008, 6:10 http://www.rbej.com/content/6/1/10tazone-treated LY mice. The data set for these DNA micro-
arrays has been deposited at the National Center for
Biotechnology Information Gene Expression Omnibus
[19] as recommended by Minimum Information About a
Microarray Experment (MIAME) standards [20] and can
be accessed through accession number GSE8806.
Relative expression of these 27 genes in untreated BL mice
(n = 2) was included for comparison (Table 2). For most
genes, pioglitazone tended to alter expression towards lev-
els seen in the BL control mice. Exceptions were RELMα
and dipeptidypeptidase 10, whose expression was similar
in vehicle-treated LY mice and untreated BL mice, but
greatly elevated in pioglitazone-treated LY mice.
Expression of RELMα in the ovary has not been previously
reported. Therefore microarray results were verified by
Real Time RT-PCR. The difference in expression of RELMα
by RT-PCR was nearly eight-fold (Figure 1), confirming a
significant increase in mRNA levels in pioglitazone-
treated mice. Since gonadal fat is a known source of
RELMα [21], we sought to confirm that the RELMα
expression was within the ovary proper. RELMα protein
was detected in mouse ovarian sections from untreated
age-matched LY mice by immunocytochemistry, confirm-
ing that RELMα was expressed within the ovary rather
than in adhering fat tissue. RELMα primarily localized in
perivascular cells, which on the basis of morphology and
distribution were likely to be macrophages, although this
was not confirmed (Figure 2). Western blot analysis of
protein extracts of vehicle- and pioglitazone-treated LY
mice did not reveal a significant difference in protein
expression (Figure 3).
Because of limited quantities of RNA extracts available
after microarray analyses, no other genes could be verified
by RT-PCR. Attempts to confirm three additional genes
yielded inconclusive results, which could not be repeated
due to depletion of the samples.
Discussion
We have previously shown that progressive obesity in
aging LY mice is associated with a concomitant diminu-
tion in ovarian function, which is paralleled by acquired
insulin and leptin resistance [16]. To our knowledge, this
is the first report demonstrating that prolonged in vivo
exposure to TZD alters intraovarian gene expression in an
aging obese mouse model. The altered expression of
numerous genes involved in diverse cellular functions
such as cell signaling, cell proliferation and survival, cell
adhesion, and differentiation suggest that the positive
effects of TZD on ovarian function observed in PCOS
patients may be multifactorial.
TZD are primarily characterized as ligands for the PPARγ.
However, pioglitazone may also activate PPARα, which
may explain its broader spectrum of clinical action rela-
Relative increase in expression of RELMα by Real Time RT-PCRFigure 1
Relative increase in expression of RELMα by Real 
Time RT-PCR. Bars represent mean ± SD, in relative gene 
expression calculated relative to endogenous GAPDH 
expression. An RNA concentration-response validation 
curve was carried out to determine the concentration of 
RNA to add to the RT-PCR reaction. All samples were run in 
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Immunolocalization of RELMα in a untreated 180-day old LY ouse varyFig re 2
Immunolocalization of RELMα in a untreated 180-
day old LY mouse ovary. VectaStain Rabbit IgG Elite ABC 
kit (Vector Laboratories, Inc., Burlingame, CA) was used on 
paraffin sections. Sections were incubated with primary anti-
body (anti-RELMα; Upstate/Chemicon, Temecula, CA) for 1 
h at RT, washed thrice, and incubated with biotinylated sec-
ond antibody for 30 min. at RT. DAB substrate (brown pre-
cipitate, arrows) was used for antigen detection, and sections 
were counterstained with hematoxylin. Scale bar = 25 μm 
(lower right).
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PPARγ isoforms results in heterodimerization with a retin-
oid X receptor (RXR), followed by the PPARγ/RXR com-
plex binding to and activating PPAR response elements on
target genes [23]. In general, PPARγ activation in adipose
cells has anti-angiogenic actions and suppresses the syn-
thesis and secretion of proinflammatory and proinsulin
resistant adipokines [24].
PPAR are widely expressed in vascular and inflammatory
cells [25]. In the ovary, PPARγ are localized in granulosa
cells of maturing follicles [26,27] and in thecal and stro-
mal macrophages [28]. In contrast, PPARα are expressed
throughout thecal and stromal regions of rodent ovaries
[26,27] consistent with vascular and peri-vascular expres-
sion.
TZD actions in the ovary have not been widely investi-
gated. Troglitazone suppressed LH and insulin-stimulated
androgen production by isolated porcine thecal cells [29].
Moreover, in human follicular fragments, TZD (pioglita-
zone and rosiglitazone) modestly inhibited testosterone
and estradiol production, but enhanced progesterone and
IGFBP-1 production [30]. These results in isolated ovarian
cells imply a direct action of TZD on steroidogenesis,
although the mechanisms remain unclear. In addition,
troglitazone suppressed inducible nitric oxide synthase
(NOS2) in mouse ovarian macrophages isolated from
preovulatory ovaries [28]. Perivascular/anti-inflammatory
actions of TZD in the ovary may also alter ovarian func-
tion.
Among genes responding to pioglitazone with altered
expression were several that participate in vascular remod-
eling. An increase in angiogenesis and stromal blood flow
are characteristic of PCOS [31,32]. Notably, leptin, angi-
opoietin, angiopoietin-like 4, and RELMα were among
the genes whose expression was altered most by pioglita-
zone treatment. The three-fold reductions in leptin and
angiopoietin mRNA expression in the current study
would be consistent with reduced angiogenesis. In con-
trast, RELMα has generally been reported to have ang-
iogenic actions [33], so the significant increase in its gene
expression in the current study may appear inconsistent.
Angiopoietin-like 4, has been reported to be both ang-
iogenic [34] and anti-angiogenic [35].
A novel finding was the intraovarian expression of RELMα
and its up-regulation by pioglitazone. Resistin and
RELMα are often co-regulated [36]. Resistin has been
shown to have significantly lower expression in mouse
models of obesity, e.g. ob/ob and db/db mice, but is stimu-
lated by PPARγ agonists [37]. Therefore the increased
expression of RELMα by pioglitazone in the current study
would be consistent, although resistin expression was not
significantly altered by pioglitazone in this study. RELMα,
also known as hypoxia-induced mitogenic factor (HIMF)
or FIZZ1, has not previously been shown to be signifi-
cantly expressed in the ovary, although it is expressed in
high levels in gonadal fat of lactating mice [21]. RELMα is
reported to be primarily associated with adipose tissue,
specifically localized in the vascular fraction [36]. The
present study demonstrates RELMα protein expression in
perivascular cells within the ovary, which are consistent in
appearance and distribution with macrophages, known
targets of TZD. However, RELMα protein levels on West-
ern blot were not siginificantly greater in pioglitazone-
treated ovaries. Considering the proximity of the immu-
noactive cells to blood vessels, it is possible that if RELMα
is secreted by these cells it could be primarily carried off in
the circulation and would not show accumulation in the
tissue.
Conclusion
Prolonged oral administration of pioglitazone to aging
obese LY mice altered the ovarian expression of a several
genes. The results suggest that PPARγ may mediate diverse
actions in the ovary, and that the positive effects of TZD
observed in women with PCOS might involve mecha-
nisms not directly related to insulin sensitivity. Further
research is needed to investigate the wide range of poten-
tial regulatory actions of PPARγ agonists in normal ovar-
ian physiology and PCOS.
Western blot of RELMα immunoactivity in vehicle- and piogl-itazone-treated LY miceFigur  3
Western blot of RELMα immunoactivity in vehicle- 
and pioglitazone-treated LY mice. Beta-actin immu-
noactivity was used as a loading control. Bar graph depicts 
the mean (+ SD) ratio of intensity of RELMα-to-actin bands. 
There was no significant difference in band intensity between 
groups.Page 6 of 8
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